Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK drops darotropium in favour of GSK573719 for COPD

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline has revised its chronic obstructive pulmonary disease (COPD) pipeline, dropping its long-acting muscarinic antagonist (LAMA) darotropium in favour of GSK573719, which has the same mechanism of action. Although darotropium had advanced into Phase IIb trials, GSK573719 is in Phase IIa development. GSK says that the move was made because GSK573719 has a better once-a-day profile in terms of the totality of its performance.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts